ストックスクリーナーアプリを入手
0.9569
4.01%
0.0369
アフターアワーズ：
.97
0.0131
+1.37%
前日終値:
$0.92
開ける：
$0.93
24時間の取引高:
29,188
Relative Volume:
0.12
時価総額：
$84.47M
収益：
-
当期純損益:
$-23.64M
株価収益率:
-3.1058
EPS:
-0.3081
ネットキャッシュフロー:
$-12.89M
1週間 パフォーマンス:
+10.38%
1か月 パフォーマンス:
+36.12%
6か月 パフォーマンス:
-37.86%
1年 パフォーマンス:
+8.74%
1日の値動き範囲:
$0.8823
$0.9649
1週間の範囲:
$0.8051
$0.9898
52週間の値動き範囲:
$0.4912
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Compare CTOR vs TAK, ZTS, TEVA, HLN, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.9569 | 81.21M | 0 | -23.64M | -12.89M | -0.3081 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-23 | アップグレード | Maxim Group | Hold → Buy |
| 2024-11-27 | 開始されました | Maxim Group | Buy |
Citius Oncology Inc (CTOR) 最新ニュース
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization - PR Newswire
Citius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms - TipRanks
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Oncology sees first international shipment of LYMPHIR to Europe - ROI-NJ
Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - simplywall.st
Citius Expands LYMPHIR Access with First European Shipment - TipRanks
Citius Oncology Begins First European Expansion of LYMPHIR - TipRanks
Citius Oncology ships first international order of LYMPHIR to Europe - TradingView
Citius Oncology Ships First International Order of LYMPHIR™ to Europe - Nasdaq
CTOR Stock Price, Quote & Chart | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill
Citius Oncology, Inc. Receives Nasdaq Compliance Notice for CTOR Common Stock – Form 8-K April 2026 Filing - Minichart
Citius Oncology Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Citius Oncology (NASDAQ: CTOR) on sub-$1 bid price and delisting risk - Stock Titan
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules - marketscreener.com
Citius Oncology announces pricing of $9 million public offering - MSN
Working capital per share of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology (NASDAQ:CTOR) Trading 9% HigherWhat's Next? - MarketBeat
CTOR Technical Analysis | Trend, Signals & Chart Patterns | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill
Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - Yahoo Finance
Aug Retail: Can Citius Oncology Inc lead its sector in growth2026 Dividend Review & AI Driven Stock Price Forecasts - baoquankhu1.vn
What is the growth rate of Citius Oncol (CTOR) Stock | Price at $0.65, Down 1.52%Stock Entry Points - Xã Vĩnh Công
Citius Oncology Inc. (CTOR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Citius Oncology reports 86% response rate in lymphoma study By Investing.com - Investing.com India
Citius Oncology reports early adoption metrics for lymphoma drug By Investing.com - Investing.com South Africa
Citius Oncology highlights early LYMPHIR commercial traction, expansion - TipRanks
Citius Oncology advances LYMPHIR launch and global expansion - TipRanks
Citius Oncology reports strong early LYMPHIR launch with broad payer coverage and institutional uptake - TradingView — Track All Markets
Black Mammoth Metals Obtains Drill Permit for Amador Silver, NV - Weekly Voice
Citius Oncology reports early adoption metrics for lymphoma drug - Investing.com
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development - PR Newswire
Can Citius Oncology Inc keep up with sector leaders2026 Pullbacks & Risk Managed Investment Entry Signals - baoquankhu1.vn
Aug PreEarnings: Should you avoid Sionna Therapeutics Inc stock right now2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
Institution Moves: Can Citius Oncology Inc lead its sector in growthTrade Exit Summary & Fast Gain Stock Tips - baoquankhu1.vn
Citius Oncology to Participate in USCLC Annual Workshop 2026, Hi - GuruFocus
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - Nasdaq
Citius Oncology (NASDAQ:CTOR) Trading Down 2.8%Here's What Happened - MarketBeat
Citius Oncology (CTOR) expands Lymphir distribution to Europe through exclusive agreement with Uniphar - MSN
If You Invested $1,000 in Citius Pharmaceuticals Inc (CTXR) - Stock Titan
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Citius Oncology, Inc.: Fundamental Analysis and Financial Ratings | CTOR | US17331Y1091 - marketscreener.com
Activity Recap: Will Citius Oncology Inc outperform small cap indexes2026 Opening Moves & Safe Entry Trade Reports - baoquankhu1.vn
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
CTOR Stock Price and Chart — NASDAQ:CTOR - TradingView
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Citius Oncology reports positive phase 1 trial data for LYMPHIR By Investing.com - Investing.com Nigeria
Citius Oncology reports positive phase 1 trial data for LYMPHIR - Investing.com Australia
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data - TipRanks
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data - TipRanks
Citius reports positive Phase 1 topline: 24% ORR, 48% CBR for LYMPHIR + pembrolizumab in gynecologic cancers - TradingView
Citius Oncology Announces Positive Topline Results from Investig - GuruFocus
Citius Oncology, Inc. Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of Lymphir in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - marketscreener.com
Citius Oncology Inc (CTOR) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
2.13%
大文字化:
|
ボリューム (24 時間):